Before revision: Despite great advances, molecular cancer pathology is often limited to use a small number of biomarkers rather than the whole transcriptome, partly due to the computational challenges.
After revision: Despite great advances, molecular cancer pathology is often limited to use a small number of biomarkers rather than the whole transcriptome, partly due to computational challenges.